Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: Low miR-31 expression with effects on proliferation and invasion

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Karnuth, Bianca ^a   Dedy, Nicolas ^b   Spieker, Tilmann ^a   Lawlor, Elizabeth R ^c   Gattenlöhner, Stefan ^d   Ranft, Andreas ^b   Dirksen, Uta ^b   Jürgens, Heribert ^b   Bräuninger, Andreas ^a,d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MICHIGAN   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 31; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FLI; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EWING SARCOMA; EX VIVO STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; SARCOMA CELL;

ADULT; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; MICRORNAS; NEOPLASM INVASIVENESS; SARCOMA, EWING;

EID: 84899709694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093067     Document Type: Article

References (46)

1. Dorfman HD, Czerniak B (1995) Bone cancers. Cancer 75: 203-210.
2. Ushigome S, Machinami R, Sorensen PH (2002) Ewing sarcoma/primitive neuroectodermal tumour. In: Fletcher CDM, Unni KK, Mertens F, editors. Tumors of soft tissue and bone.: IACR Press. 297-300.
3. Esiashvili N, Goodman M, Marcus RB Jr (2008) Changes in incidence and survival of ewing sarcoma patients over the past 3 decades: Surveillance epidemiology and end results data. J Pediatr Hematol Oncol 30: 425-430.
4. Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, et al (2003) Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 21: 85-91.
5. Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, et al (2011) Risk of recurrence and survival after relapse in patients with ewing sarcoma. Pediatr Blood Cancer 57: 549-553.
6. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
7. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al (1994) A second ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146-151. (Pubitemid 24188594)
8. Toomey EC, Schiffman JD, Lessnick SL (2010) Recent advances in the molecular pathogenesis of ewing's sarcoma. Oncogene 29: 4504-4516.
9. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, et al (2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in ewing's sarcoma. Cancer Cell 9: 405-416. (Pubitemid 43668735)
10. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, et al (2005) Development of ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468. (Pubitemid 41821703)
11. Riggi N, Suva ML, Suva D, Cironi L, Provero P, et al (2008) EWS-FLI-1 expression triggers a ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68: 2176-2185. (Pubitemid 351521790)
12. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, et al (2007) Mesenchymal stem cell features of ewing tumors. Cancer Cell 11: 421-429. (Pubitemid 46680428)
13. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, et al (2011) Modeling initiation of ewing sarcoma in human neural crest cells. PLoS One 6: e19305.
14. Griffiths-Jones S, Kozomara A (2012) miRBase: The microRNA database (release 19). 2012.
15. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
16. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
17. White NM, Fatoohi E, Metias M, Jung K, Stephan C, et al (2011) Metastamirs: A stepping stone towards improved cancer management. Nat Rev Clin Oncol 8: 75-84.
18. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, et al (2011) Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in ewing's sarcoma. Oncogene 30: 2173-2180.
19. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, et al (2011) Let-7a is a direct EWS-FLI-1 target implicated in ewing's sarcoma development. PLoS One 6: e23592.
20. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, et al (2011) A novel oncogenic mechanism in ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30: 4910-4920.
21. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, et al (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward ewing sarcoma cancer stem cells. Genes Dev 24: 916-932.
22. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, et al (2012) EWS/FLI1 regulates EYA3 in ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 10: 1048-1108.
23. Martignetti L, Laud-Duval K, Tirode F, Pierron G, Reynaud S, et al (2012) Antagonism pattern detection between MicroRNA and target expression in ewing's sarcoma. PLoS One 7: e41770.
24. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, et al (2012) miR-34a predicts survival of ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226: 796-805.
25. De Vito C, Riggi N, Cornaz S, Suva ML, Baumer K, et al (2012) A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in ewing sarcoma. Cancer Cell 21: 807-821.
26. Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, et al (2008) Results of the EICESS-92 study: Two randomized trials of ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26: 4385-4393.
27. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, et al (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47: 22-29. (Pubitemid 43787904)
28. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A (2005) Autocrine- and paracrine-activated receptor tyrosine kinases in classic hodgkin lymphoma. Blood 105: 4051-4059. (Pubitemid 40656155)
29. Benjamini Yoav, Hochberg Yosef (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 57: 289-300.
30. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
31. Kauppinen S, Vester B, Wengel J (2006) Locked nucleic acid: High-affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol (173): 405-422.
32. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, et al (2010) Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 70: 1906-1915.
33. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, et al (2010) Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 285: 22809-22817.
34. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, et al (2012) Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 21: 121-135.
35. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA (2009) Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 23: 2592-2597.
36. Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, et al (2012) Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet 57: 691-699.
37. Avigad S, Cohen IJ, Zilberstein J, Liberzon E, Goshen Y, et al (2004) The predictive potential of molecular detection in the nonmetastatic ewing family of tumors. Cancer 100: 1053-1058. (Pubitemid 38222866)
38. Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, et al (1999) EWSFLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in ewing's sarcoma. J Clin Oncol 17: 1809-1814. (Pubitemid 29269251)
39. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, et al (2010) Impact of EWS-ETS fusion type on disease progression in ewing's sarcoma/peripheral primitive neuroectodermal tumor: Prospective results from the cooperative euro-E.W.I.N.G. 99 trial. J Clin Oncol 28: 1982-1988.
40. Prieur A, Tirode F, Cohen P, Delattre O (2004) EWS/FLI-1 silencing and gene profiling of ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283. (Pubitemid 39014452)
41. Mosakhani N, Guled M, Leen G, Calabuig-Farinas S, Niini T, et al (2012) An integrated analysis of miRNA and gene copy numbers in xenografts of ewing's sarcoma. J Exp Clin Cancer Res 31: 24.
42. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, et al (2009) EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 106: 5324-5329.
43. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, et al (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1: e105.
44. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, et al (2009) MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236-2242.
45. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.
46. Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Perez-Plasencia C, Del Moral-Hernandez O, et al (2012) MetastamiRs: Non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci 13: 1347-1379.